Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
Doximity, Inc. (DOCS) reported insider activity by its Chief Financial Officer. On 11/04/2025, the officer acquired 20,200 and 2,668 shares of Class A common stock, each labeled as a code C conversion from Class B following option exercises. The option exercises were at $4.12 and $2.21 per share, respectively.
Following these transactions, the officer beneficially owned 369,793 shares of Class A common stock, held directly. Footnotes state Class B shares are convertible into Class A on a one-for-one basis at the holder’s option, with automatic conversion upon certain events. The reported stock options carry expirations on 12/21/2030 and 09/28/2030, with vesting schedules as disclosed.
Doximity, Inc. reported strong quarterly performance. Revenue for the quarter ended September 30, 2025 reached $168.5 million, up from $136.8 million a year ago. Net income was $62.1 million versus $44.2 million, and diluted EPS was $0.31 compared to $0.22. Gross profit rose to $152.1 million while operating income increased to $63.7 million.
Operating cash flow for the six months was $156.0 million. The company ended the quarter with $169.2 million in cash and cash equivalents and $709.1 million in marketable securities. Doximity repurchased and retired 4,496,467 Class A shares for $220.2 million since program inception, with $279.8 million remaining authorized. The company completed the $36.3 million Pathway Medical acquisition, adding $18.7 million of developed technology and $17.0 million of goodwill.
Doximity, Inc. filed an 8-K announcing it issued a press release with financial results for its fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except as expressly referenced. The report was signed by Chief Financial Officer Anna Bryson.
Doximity (DOCS): Director Form 4 filing. On 11/03/2025, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, converted those 2,000 Class B shares into 2,000 Class A shares, and sold 2,000 Class A shares at $66.44 per share pursuant to a Rule 10b5-1 trading plan adopted on November 12, 2024. Following these transactions, Class A Common Stock beneficially owned directly totaled 19,839 shares. The stock option was originally granted on June 10, 2020 and vests in 36 equal monthly installments starting March 27, 2020, with an expiration date of June 9, 2030.
FMR LLC8,777,627.56 shares of Doximity (DOCS) Class A common stock, representing 6.4%, with a date of event of 09/30/2025.
FMR reports sole voting power over 8,765,947.45 shares and sole dispositive power over 8,777,627.56 shares. Abigail P. Johnson reports sole dispositive power over 8,777,627.56 shares and no voting power. The filing certifies the holdings were acquired and are held in the ordinary course and not to change or influence control.
DOCS: A stockholder filed a Form 144 notice to sell 2,000 shares of common stock with an aggregate market value of $132,880. The filing lists Morgan Stanley Smith Barney as broker, an approximate sale date of November 3, 2025, and NYSE as the exchange.
The shares were acquired via a stock option exercise on November 3, 2025 for cash. Recent activity shows sales of 2,000 shares on October 1, 2025 for $140,020 and 2,000 shares on September 2, 2025 for $133,140. Shares outstanding were 136,400,248.
Doximity, Inc. (DOCS): A director reported multiple transactions on 10/10/2025. The insider exercised 5,000 stock options at an exercise price of $2.21, converted 5,000 shares of Class B Common Stock into Class A Common Stock, and sold 5,000 Class A shares at an average price of $70.84 pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2025.
Following the transactions, the insider reported 19,839 shares of Class A Common Stock held directly. The filing notes that each share of Class B Common Stock is convertible into one share of Class A Common Stock at the holder’s option, and also outlines additional automatic conversion conditions.
Doximity, Inc. (DOCS) insider filing notifies a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of
The signer affirms they are unaware of undisclosed material adverse information and, by submitting Form 144, is complying with Rule 144 notification requirements for proposed resale of restricted or control securities.
Doximity insiders reported coordinated transactions on 10/01/2025. Reporting person Kira Wampler, a director, sold 2,000 shares of Class A common stock at $70.01 and concurrently acquired 2,000 shares through conversion/exercise activity tied to outstanding Class B shares and stock options. After these transactions the reporting person beneficially owned 19,839 shares of Class A common stock and 466,700 shares of Class B common stock (equivalent to Class A on conversion). The sale executed under a pre-existing Rule 10b5-1 plan adopted on 11/12/2024, and the stock option exercised carries a $1.54 exercise price with a 06/09/2030 expiration for the vested portion.
Form 144 notice for Doximity, Inc. (DOCS): The filer reports a proposed sale of 2,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $140,020.00, expected to sell on 10/01/2025 on the NYSE. The securities were acquired on 10/01/2025 by stock option exercise and paid in cash. The filing also discloses three prior sales by the same person in the past three months: 2,000 shares on 09/02/2025 for $133,140.00, 2,000 shares on 08/01/2025 for $114,180.00, and 2,000 shares on 07/01/2025 for $121,920.00. The notice includes the standard Rule 144 signature representation regarding material nonpublic information.
FAQ
What is the current stock price of Doximity (DOCS)?
What is the market cap of Doximity (DOCS)?
